You are here

Onkos Surgical® Announces Partnership with Promimic AB for Development of Hydroxyapatite Surface Technology in Limb Salvage Surgery

PARSIPPANY, N.J., March 14, 2019 /PRNewswire/ -- Onkos Surgical, Inc. announced today that it has partnered with Promimic AB, the world's leading innovator in nano surface modification, to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery.

"At Onkos, we are focused on bringing to market innovative products and technologies that improve personalization, reduce complexity for our customers and address the clinical challenges associated with tumor surgery," said Sean Curry, SVP of Commercial Operations.  "Tumor and revision surgery can be challenging based on the complexity of the procedures and the clinical presentation inherent with the patient population.  It is well documented in literature that implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery.  These patients deserve better and the technology exists today to design implants with unique porous structures and novel surface modifications that may result in improved implant fixation.  We are excited for our partnership with Promimic as the collaboration will differentiate our ELEOS Limb Salvage Portfolio with future designs that incorporate a uniform HA treatment which maintains the integrity of novel porous structures," said Curry.

Steven Gitelis, MD, Onkos Surgical Chief Medical Officer and Associate Chief Medical Officer at Rush University said, "With advancements in cancer therapies, there are increased demands for long-term implant success.  Improved osseointegration is critical for our patients and the use of HA with orthopaedic implants is well described.  Onkos is developing the next generation of unique 3D-printed implants with novel porous structures to facilitate hard and soft tissue attachment.  The development of HA deposition on porous structure is exciting as the combination may lead to improved extracortical fixation and implant survival."

"Our unique surface technology is already clinically proven to be successful to improve osseointegration on the market for dental implants. The partnership with Onkos Surgical represents an important step for us into the orthopaedic space. The combination of technologies and working with the Onkos team is a perfect match. I strongly believe this is a start of a new era for surface enhanced implant treatments," said Magnus Larsson, Promimic CEO. "The HAnano Surface is designed to speed up integration for all types of implant materials and has unique properties to modify porous and 3D printed structures without blocking the pores."

Please note that this product is not yet cleared for sale in the United States.

About Onkos Surgical
Based in Parsippany, N.J., Onkos Surgical is a privately held surgical oncology company founded in 2015. We believe that individuals with cancer requiring surgery deserve solutions designed specifically for them.  This principle is the driving force behind our Precision Oncology initiatives.  Built on a digital platform, our solutions are rooted in unmatched expertise in patient imaging analysis, personalized surgical planning, and the latest advancements in 3D printing.  At Onkos, we are passionate about reducing complexity for our customers and addressing the clinical challenges associated with tumor surgery.

About Promimic AB
Promimic AB, based in Gothenburg, Sweden, develops and markets products within nano-materials for innovative surface treatments.  Promimic has developed the HAnano Surface that speeds up and improves the anchoring of implants in bone.  The innovative HAnano Surface is licensed to several dental and orthopedic implant companies.

Cautions Concerning Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "future," "believes," "expects," "may," "will," "should," "potential," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, the possibility that regulatory clearance will be delayed or denied, market trends, legislative and regulatory changes, cost-containment trends, product efficacy and safety concerns and supply constraints.  Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law. 

Media contacts:
Sean P. Curry
Senior Vice President, Commercial Operations 
(973) 264-5400

Ulf Brogren
President, Promimic Inc 
(512) 586-4708

Cision View original content to download multimedia:

SOURCE Onkos Surgical